
OPKO Health OPK
$ 1.15
2.68%
Quarterly report 2025-Q2
added 07-31-2025
OPKO Health Accounts Receivables 2011-2026 | OPK
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118 M | 123 M | 127 M | 260 M | 286 M | 135 M | 144 M | 166 M | 220 M | 194 M | 20 M | 19.8 M | 21.2 M | 12.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 286 M | 12.5 M | 132 M |
Quarterly Accounts Receivables OPKO Health
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 99.4 M | 96.2 M | 107 M | 105 M | 111 M | 117 M | 211 M | 121 M | 127 M | 123 M | - | 213 M | 260 M | 255 M | 266 M | 320 M | 286 M | 286 M | 286 M | 286 M | 135 M | 135 M | 135 M | 135 M | 144 M | 144 M | 144 M | 144 M | 166 M | 166 M | 166 M | 166 M | 220 M | 220 M | 220 M | 220 M | 194 M | 194 M | 194 M | 194 M | 20 M | 20 M | 20 M | 20 M | 19.8 M | 19.8 M | 19.8 M | 19.8 M | 21.2 M | 21.2 M | 21.2 M | 21.2 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 320 M | 12.5 M | 135 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Biomerica
BMRA
|
731 K | $ 2.13 | -2.74 % | $ 4.89 M | ||
|
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | ||
|
Castle Biosciences
CSTL
|
51.2 M | $ 25.75 | 3.0 % | $ 715 M | ||
|
Quest Diagnostics Incorporated
DGX
|
1.41 B | $ 195.6 | 0.17 % | $ 21.7 B | ||
|
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | ||
|
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | ||
|
DexCom
DXCM
|
1.22 B | $ 65.94 | -1.51 % | $ 25.7 B | ||
|
Co-Diagnostics
CODX
|
304 K | $ 4.4 | 101.83 % | $ 129 M | ||
|
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
299 M | $ 104.91 | - | $ 19.8 B | ||
|
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | ||
|
Fulgent Genetics
FLGT
|
69 M | $ 16.33 | 5.29 % | $ 494 M | ||
|
Charles River Laboratories International
CRL
|
709 M | $ 158.0 | 2.86 % | $ 7.83 B | ||
|
IQVIA Holdings
IQV
|
3.4 B | $ 166.96 | 0.54 % | $ 28.7 B | ||
|
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
96.1 M | - | - | $ 21.2 M | ||
|
BioNano Genomics
BNGO
|
5.2 M | $ 1.46 | 26.96 % | $ 1.86 M | ||
|
Interpace Biosciences
IDXG
|
8.54 M | $ 1.71 | 0.73 % | $ 7.5 M | ||
|
IDEXX Laboratories
IDXX
|
552 M | $ 578.51 | 0.22 % | $ 46.5 B | ||
|
Agilent Technologies
A
|
1.17 B | $ 112.02 | 0.65 % | $ 34.1 B | ||
|
Illumina
ILMN
|
735 M | $ 123.79 | -0.43 % | $ 19.7 B | ||
|
ICON Public Limited Company
ICLR
|
1.34 B | $ 100.35 | 0.65 % | $ 8.28 B | ||
|
DarioHealth Corp.
DRIO
|
2.14 M | $ 7.5 | -6.13 % | $ 29.9 M | ||
|
Guardant Health
GH
|
138 M | $ 84.9 | -0.33 % | $ 10.6 B | ||
|
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B | ||
|
CareDx, Inc
CDNA
|
42.6 M | $ 17.56 | 2.39 % | $ 936 M | ||
|
Lantheus Holdings
LNTH
|
359 M | $ 75.73 | -0.92 % | $ 5.11 B | ||
|
Medpace Holdings
MEDP
|
402 M | $ 456.93 | 0.98 % | $ 13.2 B | ||
|
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
2.1 B | $ 264.42 | 0.54 % | $ 22 B | ||
|
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
778 M | $ 1 239.07 | 2.87 % | $ 25.5 B | ||
|
Myriad Genetics
MYGN
|
115 M | $ 4.66 | 1.75 % | $ 432 M | ||
|
ENDRA Life Sciences
NDRA
|
6.85 K | $ 3.48 | 0.87 % | $ 1.87 M | ||
|
NeoGenomics
NEO
|
159 M | $ 8.1 | 1.76 % | $ 1.04 B | ||
|
National Research Corporation
NRC
|
11.1 M | $ 17.51 | 1.1 % | $ 392 M | ||
|
Natera
NTRA
|
244 M | $ 200.09 | 2.46 % | $ 19.7 B | ||
|
Pacific Biosciences of California
PACB
|
35.4 M | $ 1.39 | 4.51 % | $ 417 M | ||
|
RadNet
RDNT
|
200 M | $ 61.74 | 0.41 % | $ 4.64 B | ||
|
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B |